What is ReShape Lifesciences Inc.'s earnings per share (EPS)?

ReShape Lifesciences Inc. (RSLS) reported diluted earnings per share of -$4.86 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ReShape Lifesciences Inc. (RSLS) Financials

RSLS

FY2025 annual

Revenue $320K +24.4% YoY

Net Income -$10.3M -609.0% YoY

EPS (Diluted) -$4.86 YoY not available

Operating Cash Flow -$3.7M -510.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RSLS SEC filings page.

ReShape Lifesciences Inc. (RSLS) reported $320K in revenue for fiscal year 2025, up 24.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RSLS FY2025 2026-08-30

ReShape’s dominant mechanic is a development-stage cost base operating far ahead of a sharply diminished revenue stream.

Revenue fell from $8.7M in FY2023 to $320K in FY2025, yet gross-margin performance stayed comparatively intact; the problem is therefore scale absorption, with operating costs overwhelming the remaining sales rather than a collapse in reported product-level margin. FY2025 net loss of -$10.3M was materially larger than operating cash outflow of -$3.7M, indicating that accounting losses included substantial noncash or non-operating effects while the cash burden was smaller but still ongoing.

FY2025 restored positive equity after the FY2024 deficit, and the current ratio recovered to 2.0x from 0.1x; short-term balance-sheet flexibility improved, but this does not change the company’s limited operating scale.

Financing cash flow supplied $8.7M while operations consumed $3.7M, so funding—not internally generated cash—supported the period’s liquidity. Reported liquidity equaled 15.9 months of the latest annual operating outflow, a historical balance-to-outflow comparison rather than evidence of operating self-sufficiency.

Financial Health Signals

Financial health score not available

ReShape Lifesciences Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-21.58

ReShape Lifesciences Inc. scores -21.58, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.4M) relative to total liabilities ($2.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

ReShape Lifesciences Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

ReShape Lifesciences Inc. reported a net loss of $10.3M while operations used $3.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ReShape Lifesciences Inc. reported an operating loss of $10.5M against $147K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$32K

YoY-84.1%

ReShape Lifesciences Inc. generated $32K in revenue in Q1 2026. This represents a decrease of 84.1% from the same quarter a year earlier.

EBITDA

-$1.1M

YoY-476.7%

ReShape Lifesciences Inc.'s EBITDA was -$1.1M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 476.7% from the same quarter a year earlier.

Net Income

-$963K

YoY-227.5%

ReShape Lifesciences Inc. reported -$963K in net income in Q1 2026. This represents a decrease of 227.5% from the same quarter a year earlier.

EPS (Diluted)

-$0.15

ReShape Lifesciences Inc. earned -$0.15 per diluted share (EPS) in Q1 2026.

Cash & Balance Sheet

Cash & Debt

$8.8M

QoQ+76.5%

ReShape Lifesciences Inc. held $8.8M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+18.6%

5Y CAGR-6.9%

ReShape Lifesciences Inc. had 7M shares outstanding in Q1 2026. Against the prior quarter it is up 18.6%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

52.7%

YoY-25.1pp

ReShape Lifesciences Inc.'s gross margin was 52.7% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 25.1 percentage points from the same quarter a year earlier.

Return on Equity

-12.0%

YoY+11.9pp

ReShape Lifesciences Inc.'s ROE was -12.0% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 11.9 percentage points from the same quarter a year earlier.

Operating Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$666K

YoY+638.3%

ReShape Lifesciences Inc. invested $666K in research and development in Q1 2026. This represents an increase of 638.3% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

RSLS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RSLS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	$320K+24.4%	$257K-97.0%	$8.7M-22.8%	$11.2M-17.4%	$13.6M+20.4%	$11.3M+244.4%	$3.3M-63.9%	$9.1M-8.2%	$9.9M+192.2%	$3.4M-16.0%	$4.0M+14.1%	$3.5M
Cost of Revenue	N/A	$101K+62.9%	$62K-98.0%	$3.1M-29.5%	$4.4M-15.5%	$5.3M+4.3%	$5.0M+70.7%	$3.0M-45.6%	$5.4M+12.3%	$4.8M+71.9%	$2.8M+12.2%	$2.5M-14.0%	$2.9M
Gross Profit	N/A	$219K+12.2%	$195K-96.5%	$5.5M-18.4%	$6.8M-18.5%	$8.3M+33.3%	$6.3M+1791.8%	$331K-91.0%	$3.7M-27.7%	$5.1M+770.7%	$584K-62.0%	$1.5M+145.0%	$627K
R&D Expenses	N/A	$588K+106.1%	$285K-87.7%	$2.3M-8.8%	$2.5M+7.1%	$2.4M-32.3%	$3.5M-49.3%	$6.9M-35.6%	$10.7M+0.5%	$10.6M+7.9%	$9.9M-23.9%	$13.0M+125.0%	$5.8M
SG&A Expenses	N/A	$2.4M+163.3%	$899K-88.1%	$7.5M-46.4%	$14.1M+58.5%	$8.9M+89.5%	$4.7M-71.8%	$16.7M-44.3%	$29.9M+3.9%	$28.8M+182.2%	$10.2M+192.7%	$3.5M-25.7%	$4.7M
Operating Income	N/A	-$10.5M-938.7%	-$1.0M+93.5%	-$15.4M+66.8%	-$46.4M+19.9%	-$57.9M-364.7%	-$12.5M+46.4%	-$23.2M+37.2%	-$37.0M-7.5%	-$34.4M-76.3%	-$19.5M-30.6%	-$14.9M-51.8%	-$9.8M
EBITDA	N/A	-$10.4M-955.7%	-$989K+93.5%	-$15.2M+65.5%	-$44.2M+20.9%	-$55.9M-361.4%	-$12.1M+46.7%	-$22.8M	N/A	-$34.1M-76.4%	-$19.3M-30.8%	-$14.8M-52.6%	-$9.7M
Interest Expense	N/A	$147K-28.8%	$206K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	$39K-25.0%	$52K+113.7%	-$380K-38.7%	-$274K-51.4%	-$181K-1392.9%	$14K+27.3%	$11K+10.0%	$10K+400.0%	$2K+115.4%	-$13K-181.3%	$16K
Net Income	N/A	-$10.3M-609.0%	-$1.4M+87.3%	-$11.4M+75.4%	-$46.2M+26.8%	-$63.1M-191.9%	-$21.6M+8.6%	-$23.7M+36.7%	-$37.4M-7.5%	-$34.8M-69.9%	-$20.5M-31.6%	-$15.6M-57.3%	-$9.9M
EPS (Basic)	N/A	-$4.86+99.9%	-$6001.39-5313.0%	-$110.87-1.8%	-$108.90+62.3%	-$288.97-5106.7%	-$5.55	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$4.86	-$6001.39	-$110.87	-$108.90	-$288.97	-$5.55	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	241	102,707	424,390	218,522	4M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24	Q2'2410-Q
Revenue	$32K-84.1%	N/A	$35K-59.0%	$1.2M-36.8%	$199K-89.8%	N/A	$85K-96.1%	$2.0M-12.8%
Cost of Revenue	$15K-66.2%	N/A	$17K-65.1%	$643K-22.6%	$44K-94.3%	N/A	$47K-94.5%	$831K-21.6%
Gross Profit	$17K-89.2%	N/A	$18K-51.3%	$599K-47.2%	$154K-86.7%	N/A	$37K-97.1%	$1.1M-5.0%
R&D Expenses	$666K+638.3%	N/A	$40K-40.6%	$476K+19.3%	$90K-81.3%	N/A	$67K-87.7%	$399K-31.3%
SG&A Expenses	$478K+83.9%	N/A	$844K+242.1%	$1.6M+137.5%	$260K-74.5%	N/A	$247K-86.2%	$670K-69.2%
Operating Income	-$1.1M-467.8%	N/A	-$8.6M-2951.6%	-$2.8M-34.5%	-$199K+91.0%	N/A	-$281K+92.8%	-$2.1M+48.3%
EBITDA	-$1.1M-476.7%	N/A	-$8.6M-2999.4%	N/A	-$195K+91.1%	N/A	-$277K	N/A
Interest Expense	$3K-94.8%	N/A	$26K-44.0%	N/A	$55K	N/A	$46K	N/A
Income Tax	N/A	N/A	N/A	$8K-46.7%	$7K-50.0%	N/A	$6K+100.0%	$15K+275.0%
Net Income	-$963K-227.5%	N/A	-$8.4M-1439.7%	-$2.6M-64.9%	-$294K+86.6%	N/A	-$548K+84.5%	-$1.6M+54.3%
EPS (Basic)	-$0.15+100.0%	N/A	-$3.12-119.9%	-$2.25-2356.3%	-$761.59-562374.2%	N/A	-$1.42+97.6%	-$0.09+91.5%
EPS (Diluted)	-$0.15	N/A	-$3.12	-$2.25	-$761.59	N/A	-$1419.10	-$91.56
Diluted Shares (Avg)	7M	N/A	3M	1M	386	N/A	386	17,421

RSLS Balance Sheet

RSLS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Total Assets	$6.5M+370.3%	$1.4M-87.0%	$10.7M-4.3%	$11.1M-78.8%	$52.5M+41.7%	$37.1M+81.7%	$20.4M-32.9%	$30.4M-42.8%	$53.1M-32.6%	$78.8M+454.0%	$14.2M	N/A
Current Assets	$5.4M+1700.5%	$302K-97.1%	$10.3M+3.9%	$9.9M-66.9%	$29.9M+234.7%	$8.9M-51.0%	$18.2M-36.3%	$28.6M-44.6%	$51.8M-33.7%	$78.1M+465.5%	$13.8M	N/A
Cash & Equivalents	$5.0M+4789.2%	$102K-97.7%	$4.5M+15.7%	$3.9M-83.1%	$22.8M+669.9%	$3.0M-79.0%	$14.1M-33.7%	$21.2M+0.4%	$21.1M-71.1%	$73.0M+2074.5%	$3.4M-51.4%	$6.9M
Short-Term Investments	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	$3.7M+3.6%	$3.6M+20.2%	$3.0M+33.8%	$2.2M+15.9%	$1.9M+22.5%	$1.6M+11.4%	$1.4M+71.5%	$827K+127.8%	$363K	N/A
Accounts Receivable	$325-85.8%	$2K-99.9%	$1.7M	N/A	N/A	N/A	$285K-67.2%	$870K-79.4%	$4.2M	$0	N/A	N/A
Long-Term Investments	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.7M-52.6%	$5.8M-65.7%	$16.8M+125.1%	$7.5M-8.7%	$8.2M-63.7%	$22.6M+707.8%	-$3.7M-121.5%	$17.3M-3.9%	$18.0M+24.3%	$14.5M-79.1%	$69.4M	N/A
Current Liabilities	$2.7M-52.3%	$5.7M+52.0%	$3.8M-49.5%	$7.5M-0.7%	$7.5M-35.1%	$11.6M+191.8%	$4.0M-76.9%	$17.2M+72.1%	$10.0M+118.0%	$4.6M-17.5%	$5.6M	N/A
Non-Current Liabilities	$0-100.0%	$33K-99.7%	$13.1M	$0-100.0%	$667K-93.9%	$11.0M+1834.4%	$567K+1081.3%	$48K-99.4%	$8.0M-19.3%	$9.9M-84.5%	$63.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$9.2M	$0	$0-100.0%	$8.0M-19.4%	$9.9M+8.7%	$9.1M	N/A
Total Equity	$3.8M+185.7%	-$4.4M+28.9%	-$6.2M-268.6%	$3.7M-91.7%	$44.3M+206.0%	$14.5M-39.9%	$24.1M+83.9%	$13.1M-62.7%	$35.1M-45.4%	$64.3M+216.6%	-$55.1M-38.3%	-$39.9M
Retained Earnings	-$87.6M-58.0%	-$55.4M+91.3%	-$635.6M-1.8%	-$624.2M-8.0%	-$578.0M-12.3%	-$514.8M-198.6%	-$172.4M-15.9%	-$148.8M-33.6%	-$111.4M-45.4%	-$76.6M-36.5%	-$56.1M	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24	Q2'2410-Q
Total Assets	$10.2M+605.8%	$6.5M+370.3%	$7.0M+451.2%	$1.6M+17.9%	$1.4M-82.5%	$1.4M-87.0%	$1.3M-83.7%	$1.4M-88.4%
Current Assets	$9.2M	$5.4M+1700.5%	$6.0M	$584K	N/A	$302K-97.1%	N/A	N/A
Cash & Equivalents	$8.8M	$5.0M+4789.2%	$5.7M+668.1%	$383K+3094.9%	N/A	$102K-97.7%	$743K-48.7%	$12K-99.7%
Accounts Receivable	$309-100.0%	$325-85.8%	$23K-98.2%	$341-100.0%	$700K-56.3%	$2K-99.9%	$1.3M	$1.4M
Total Liabilities	$2.1M+906.2%	$2.7M-52.6%	$3.1M+1598.3%	$6.6M+23.7%	$213K-94.2%	$5.8M-65.7%	-$209K-104.4%	$5.4M+4.6%
Current Liabilities	$2.1M	$2.7M-52.3%	$3.1M-22.5%	$6.6M+106.3%	N/A	$5.7M+52.0%	$4.0M-9.9%	$3.2M-27.3%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$8K+100.2%	$17K-99.2%	$1.1M+534.8%	$33K-99.7%	-$4.2M-1639.5%	$2.1M+202.8%
Total Equity	$8.0M+553.8%	$3.8M+185.7%	$2.5M+70.1%	-$5.0M-25.7%	$1.2M-72.9%	-$4.4M+28.9%	$1.5M-51.8%	-$4.0M-158.9%
Retained Earnings	-$88.5M+86.2%	-$87.6M-58.0%	-$86.3M+86.5%	-$56.0M+91.2%	-$641.2M-0.5%	-$55.4M+91.3%	-$640.9M-1.1%	-$639.4M-1.4%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

RSLS Cash Flow Statement

RSLS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$5.0M	-$3.7M-510.4%	-$614K+96.4%	-$17.0M+22.6%	-$21.9M-42.5%	-$15.4M-79.8%	-$8.6M+62.6%	-$22.9M+22.3%	-$29.4M+3.9%	-$30.6M-58.1%	-$19.4M-70.0%	-$11.4M-15.0%	-$9.9M
Depreciation & Amortization	N/A	$12K-30.9%	$17K-88.7%	$154K-92.8%	$2.2M+9.2%	$2.0M+479.7%	$340K-29.0%	$479K	N/A	$330K+71.9%	$192K+15.0%	$167K+0.6%	$166K
Stock-Based Compensation	N/A	$577K+213.7%	$184K-76.0%	$766K-63.3%	$2.1M-82.9%	$12.2M+824.2%	$1.3M-55.6%	$3.0M-36.4%	$4.7M+44.8%	$3.2M+475.7%	$563K+172.0%	$207K+11.9%	$185K
Capital Expenditures	N/A	N/A	N/A	$43K-67.2%	$131K-62.8%	$352K+105.8%	$171K-11.9%	$194K-84.9%	$1.3M+22.9%	$1.0M+196.3%	$352K+153.2%	$139K-48.1%	$268K
Free Cash Flow	N/A	N/A	N/A	-$17.0M+22.8%	-$22.0M-40.1%	-$15.7M-80.3%	-$8.7M+62.2%	-$23.1M+24.9%	-$30.7M+3.0%	-$31.7M-60.6%	-$19.7M-71.0%	-$11.5M-13.3%	-$10.2M
Investing Cash Flow	N/A	N/A	$315+103.2%	-$10K+89.1%	-$92K-105.0%	$1.9M+177.6%	-$2.4M-201.4%	$2.4M-87.9%	$19.5M+189.3%	-$21.9M-452.5%	$6.2M+123.3%	$2.8M+135.1%	-$7.9M
Financing Cash Flow	$13.8M	$8.7M+1140.1%	$698K-96.0%	$17.6M+461.5%	$3.1M-90.6%	$33.3M+200.7%	$11.1M-17.2%	$13.4M+33.9%	$10.0M+1530.3%	$613K-99.3%	$82.8M+1535.4%	$5.1M-77.2%	$22.2M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24	Q2'2410-Q
Operating Cash Flow	-$1.4M-605.5%	-$1.5M-49704.5%	-$1.8M-373.1%	-$297K-116.2%	-$204K+90.2%	-$3K+99.9%	-$374K+86.5%	$1.8M+127.5%
Depreciation & Amortization	$3K-26.1%	N/A	$3K-36.6%	N/A	$4K-41.3%	N/A	$4K	N/A
Stock-Based Compensation	$6K-62.0%	N/A	$574K+1694.1%	$12K-81.5%	$15K-79.2%	N/A	$32K-85.2%	$65K-70.0%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$1K	$274	N/A
Financing Cash Flow	$5.3M+3205.5%	$764K+1329.0%	$7.1M+2498.8%	$622K	$160K	$53K-99.0%	$274K+180.9%	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

RSLS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RSLS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Gross Margin	68.4%-7.5pp	75.9%+12.0pp	63.9%+3.4pp	60.5%-0.9pp	61.4%+6.0pp	55.4%+45.3pp	10.1%-30.3pp	40.4%-10.9pp	51.3%+34.1pp	17.2%-20.8pp	38.0%+20.3pp	17.7%
Operating Margin	-3269.3%	-391.7%	-177.3%	-412.4%	-425.6%	-110.3%	-708.0%	-406.2%	-346.9%	-574.9%	-369.7%	-278.0%
Net Margin	-3209.7%	-563.3%	-131.2%	-411.2%	-464.3%	-191.4%	-721.6%	-410.7%	-350.7%	-603.2%	-385.2%	-279.5%
Return on Equity	-272.8%	N/A	N/A	-1262.3%-1119.9pp	-142.4%+6.9pp	-149.3%-51.1pp	-98.2%+187.0pp	-285.2%-186.2pp	-99.0%-67.2pp	-31.8%	N/A	N/A
Return on Assets	-157.9%-53.2pp	-104.8%+2.0pp	-106.8%+308.0pp	-414.8%-294.6pp	-120.2%-61.8pp	-58.4%+57.7pp	-116.1%+6.9pp	-123.0%-57.6pp	-65.5%-39.5pp	-26.0%+83.4pp	-109.4%	N/A
Current Ratio	1.99+1.9x	0.05-2.7x	2.73+1.4x	1.32-2.7x	3.98+3.2x	0.77-3.8x	4.59+2.9x	1.66-3.5x	5.17-11.8x	17.00+14.5x	2.48	N/A
Debt-to-Equity	0.73	N/A	N/A	2.04+1.9x	0.18-0.4x	0.63+0.6x	0.000.0x	0.00-0.2x	0.23+0.1x	0.15	N/A	N/A
Asset Turnover	0.05-0.1x	0.19-0.6x	0.81-0.2x	1.01+0.7x	0.260.0x	0.30+0.1x	0.16-0.1x	0.30+0.1x	0.19+0.1x	0.04-0.2x	0.28	N/A
FCF Margin	N/A	N/A	-195.9%	-196.0%	-115.6%	-77.2%	-702.8%	-337.5%	-319.4%	-581.2%	-285.5%	-287.5%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24	Q2'2410-Q
Gross Margin	52.7%-25.1pp	N/A	52.1%+8.3pp	48.2%-9.5pp	77.8%+17.8pp	N/A	43.9%-15.9pp	57.7%+4.7pp
Operating Margin	-3576.8%	N/A	-24761.9%	-222.4%	-100.2%	N/A	-332.4%	-104.5%
Net Margin	-3048.0%	N/A	-24356.2%	-211.8%	-148.0%	N/A	-648.1%	-81.2%
Return on Equity	-12.0%+11.9pp	N/A	-333.4%-296.6pp	N/A	-23.9%+24.5pp	N/A	-36.8%+77.8pp	N/A
Return on Assets	-9.4%+10.9pp	N/A	-119.7%-76.9pp	-161.8%-46.1pp	-20.4%+6.3pp	N/A	-42.9%+2.3pp	-115.7%-86.2pp
Current Ratio	4.27	1.99+1.9x	1.94	0.09	N/A	0.05-2.7x	N/A	N/A
Debt-to-Equity	0.27+0.1x	0.73	1.24	N/A	0.17-0.6x	N/A	N/A	N/A
Asset Turnover	0.00-0.1x	N/A	0.00-0.1x	0.76-0.7x	0.14-0.1x	N/A	0.07-0.2x	1.43+1.2x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ReShape Lifesciences Inc. RSLS	FY2025	$320K	-$10.3M	N/A	$9.4M	—
Pavmed PAVM	FY2025	$71K	-$3.8M	N/A	$42.2M	—
Lifeward Ltd LFWD	FY2025	$22.0M	-$19.9M	-90.4%	$19.8M	47/100
Biomerica Inc BMRA	FY2026	$4.5M	-$3.8M	-84.8%	$10.6M	44/100
DIH Holdings US DHAI	FY2025	$62.9M	-$8.7M	-13.8%	$1.6M	—
HeartSciences Inc HSCS	FY2026	$4K	-$9.1M	N/A	$16.8M	—

Where ReShape Lifesciences Inc. Ranks

Frequently Asked Questions

What is ReShape Lifesciences Inc.'s annual revenue?

ReShape Lifesciences Inc. (RSLS) reported $320K in total revenue for fiscal year 2025. This represents a 24.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ReShape Lifesciences Inc.'s revenue growing?

ReShape Lifesciences Inc. (RSLS) revenue grew by 24.4% year-over-year, from $257K to $320K in fiscal year 2025.

Is ReShape Lifesciences Inc. profitable?

No, ReShape Lifesciences Inc. (RSLS) reported a net income of -$10.3M in fiscal year 2025.

What is ReShape Lifesciences Inc.'s EBITDA?

ReShape Lifesciences Inc. (RSLS) had EBITDA of -$10.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ReShape Lifesciences Inc.'s gross margin?

ReShape Lifesciences Inc. (RSLS) had a gross margin of 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ReShape Lifesciences Inc.'s return on equity (ROE)?

ReShape Lifesciences Inc. (RSLS) has a return on equity of -272.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ReShape Lifesciences Inc.'s operating cash flow?

ReShape Lifesciences Inc. (RSLS) recorded an outflow of $3.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are ReShape Lifesciences Inc.'s total assets?

ReShape Lifesciences Inc. (RSLS) had $6.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does ReShape Lifesciences Inc. spend on research and development?

ReShape Lifesciences Inc. (RSLS) invested $588K in research and development during fiscal year 2025.

How many shares does ReShape Lifesciences Inc. have outstanding?

ReShape Lifesciences Inc. (RSLS) had 6M shares outstanding as of fiscal year 2025.

What is ReShape Lifesciences Inc.'s current ratio?

ReShape Lifesciences Inc. (RSLS) had a current ratio of 1.99 as of fiscal year 2025, which is generally considered healthy.

What is ReShape Lifesciences Inc.'s debt-to-equity ratio?

ReShape Lifesciences Inc. (RSLS) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ReShape Lifesciences Inc.'s return on assets (ROA)?

ReShape Lifesciences Inc. (RSLS) had a return on assets of -157.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does ReShape Lifesciences Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, ReShape Lifesciences Inc. (RSLS) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.7M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ReShape Lifesciences Inc.'s Altman Z-Score?

ReShape Lifesciences Inc. (RSLS) has an Altman Z-Score of -21.58, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ReShape Lifesciences Inc.'s Piotroski F-Score?

ReShape Lifesciences Inc. (RSLS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ReShape Lifesciences Inc.'s earnings high quality?

ReShape Lifesciences Inc. (RSLS) reported a net loss of $10.3M while operations used $3.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ReShape Lifesciences Inc. cover its interest payments?

ReShape Lifesciences Inc. (RSLS) reported an operating loss of $10.5M against $147K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.